36 Results for "

TT

" in MedChemExpress (MCE) Product Catalog:
Products (36)

36 Results for "TT" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-P9909
CAS No.: 815610-63-0
Synonyms: CNTO-1275; L04AC05; TT-20

Target:  

Interleukin Related

Research Areas:  

Inflammation/Immunology Cancer

Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P99459
CAS No.: 909110-25-4
Synonyms: BG 9924; TT-47

Target:  

TNF Receptor CXCR

Research Areas:  

Inflammation/Immunology

Baminercept (BG 9924; TT-47) is an Ig fusion protein targeting the lymphotoxin β receptor (LTβR). Baminercept effectively regulates subsets of circulating immune cells by inhibiting LIGHT, LT-α1β2 and their receptors. Baminercept also increases blood lymphocyte counts and reduces plasma CXCL13 levels. Baminercept carries a high risk of hepatotoxicity. Baminercept can be used in research on rheumatoid arthritis and primary Sjögren's syndrome .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-125016
CAS No.: 2230640-94-3
Purity:  99.78%
Synonyms: TAZ-K
Target:  

YAP

Research Areas:  

Cardiovascular Disease Cancer

TT-10 (TAZ-K) is an activator of YES-associated protein (YAP)-transcriptional enhancer factor domain (TEAD) activity. TT-10 can be used for the research of heart diseases accompanied by cardiomyocyte loss .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-156483
CAS No.: 1164471-33-3
Purity:  99.76%
TT-012 is a MITF inhibitor with a human MITF IC50 of 13.1 nM and a human MITF Kd value of 15.5 nM. TT-012 reduces mRNA levels of MITF downstream genes linked to melanosome biogenesis, cell survival, and proliferation, and upregulates cell cycle-inhibiting genes. TT-012 can be used for the research of melanoma[1][2][3].
loading...
    loading...
Cat. No.: HY-P99160
CAS No.: 219649-07-7
Synonyms: hMN14

Research Areas:  

Cancer

Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy .
loading...
    loading...
Cat. No.: HY-129658A
CAS No.: 2382719-60-8
Purity:  99.77%
Target:  

GCGR

Research Areas:  

Metabolic Disease

TT-OAD2 is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. TT-OAD2 has the potential for diabetes treatment .
loading...
    loading...
Cat. No.: HY-148049
CAS No.: 1821214-50-9
Purity:  ≥98.0%
TT3 is an ionizable lipid-like material and a lipid nanoparticle (LLNs)-based mRNA delivery vector. TT3 exhibits liver and spleen specificity and excellent delivery efficiency .
loading...
    loading...
Cat. No.: HY-145601
CAS No.: 2230490-29-4
Purity:  98.45%
Synonyms: TT 00420
Target:  

Aurora Kinase FGFR VEGFR

Research Areas:  

Cancer

Tinengotinib (TT00420) is an orally active, spectrally selective small molecule kinase inhibitor targeting Aurora A/B (IC50=1.2-3.3 nM), FGFR1/2/3 (IC50=1.5-3.5 nM), VEGFRs, JAK1/2 and CSF1R. Tinengotinib blocks Aurora kinase-mediated cell cycle progression (inducing G2/M arrest), inhibits FGFR/JNK-JUN signaling pathway and activates MEK/ERK-dependent apoptotic pathway. Tinengotinib has the activity of anti-tumor proliferation, inducing apoptosis, inhibiting angiogenesis and regulating tumor microenvironment. Tinengotinib can be used in the study of triple-negative breast cancer (TNBC), gallbladder cancer and tumor immune microenvironment .
loading...
    loading...
Cat. No.: HY-124611
CAS No.: 1627126-59-3
Purity:  98.47%
Target:  

HSP Apoptosis

Research Areas:  

Cancer

JG-231 is an allosteric inhibitor of heat shock protein 70 (Hsp70). JG - 231 inhibits the binding of Hsp70 and BAG family proteins, including inhibition of Hsp70 and BAG1 with a Ki of 0.11 μM. JG-231 inhibits proliferation of tumor cells and induces apoptosis. JG-231 has antitumor activity .
loading...
    loading...
Cat. No.: HY-129652
CAS No.: 2241668-45-9
Purity:  96.28%
Target:  

AUTACs

Research Areas:  

Cancer

HaloAUTAC tt15 is an autophagy-targeting chimera (AUTAC), that targets the Halo Tag carrying proteins, and degrades via the autophagy mechanism .
loading...
    loading...
Cat. No.: HY-114520
CAS No.: 1022367-69-6
Purity:  99.38%
TT01001 is a selective and orally active mitoNEET agonist and a monoamine oxidase B (MAO-B) inhibitor (IC50 = 8.84 μM). TT01001 does not activate PPARγ but interacts with MitoNEET. TT01001 attenuates oxidative stress and neuronal apoptosis by preventing mitoNEET-mediated mitochondrial dysfunction. TT01001 improves type II diabetes and ameliorates mitochondrial function of mice. TT01001 can used for the studies of type II diabetes and neurological disorders .
loading...
    loading...
Cat. No.: HY-105172
CAS No.: 147159-51-1
Purity:  98.27%
Synonyms: CAP-232; TLN-232
Target:  

Somatostatin Receptor

Research Areas:  

Inflammation/Immunology Cancer

TT-232 (CAP-232), a somatostatin derivative, is a peptide SSTR1/SSTR4 agonist. TT-232 inhibits cancer cell proliferation and induces apoptosis. TT-232 is also a broad-spectrum anti-inflammatory and analgesic agent .
loading...
    loading...
Cat. No.: HY-156135
CAS No.: 5358-76-9
Purity:  ≥98.0%
NSC194598 is a p53 DNA-binding inhibitor with an IC50 value of 180 nM. NSC194598 inhibits p53 DNA binding and induction of target genesn when p53 is stabilized and activated by irradiation or chemotherapy. NSC194598 can interfere with transcriptional activation of mutated rearranged during transfection (RET) gene, induce apoptosis and G0/G1 phase arrest. NSC194598 can be used for the researches of acute radiation toxicity and medullary thyroid carcinoma .
loading...
    loading...
Cat. No.: HY-101246
CAS No.: 269730-03-2
Purity:  99.29%
Target:  

RET

Research Areas:  

Cancer

RPI-1 is a specific, orally available 2-indolinone Ret tyrosine kinase inhibitor. RPI-1 inhibits proliferation, Ret tyrosine phosphorylation, Ret protein expression, and the activation of PLCgamma, ERKs and AKT in human medullary thyroid carcinoma TT cells. Antitumor activity .
loading...
    loading...
Cat. No.: HY-N2138
CAS No.: 152580-79-5
Buddlejasaponin IVb (Compound 2), a triterpene saponin isolated from Clinopodium chinense (Benth.) O. Kuntze, Compound 2 has hemostasis efficacy, shortens thrombin time (TT) by 20.6 % .
loading...
    loading...
Cat. No.: HY-P5425A
Research Areas:  

Cancer

Tetanus Toxin (830–844) TFA is a biological active peptide. (tetanus toxin-derived peptide TT830–844 CD4 + T-cell epitope. This promiscuous CD4 + T-cell epitope can bind to a wide range of HLA–DRB molecules and is thus expected to activate CD4 + T-cell responses in a large part of the human population) .
loading...
    loading...
Cat. No.: HY-156906
CAS No.: 1648707-79-2
Purity:  98.15%
Target:  

MDM-2/p53

Research Areas:  

Cancer

UNC3474 is a small molecule ligand, binding with 53BP1. UNC3474 binds the aromatic methyl-lysine binding cage of 53BP1 TT, with a dissociation constant (Kd) of 1.0 ± 0.3 μM. UNC3474 inhibits the recruitment of 53BP1 to DSBs by stabilizing a pre-existing autoinhibited state of 53BP1 in cells .
loading...
    loading...
Cat. No.: HY-160902
CAS No.: 2241668-58-4
Target:  

Autophagy AUTACs

Research Areas:  

Others

2G-HaloAUTAC (Compound tt44) is a Autophagy-targeting chimera (2G-HaloAUTAC) that improves the activity of AUTACs by replacing the L-Cysteine ​​(L-Cys) linker with other structures. 2G-HaloAUTAC exhibits degradation activity against EGFP-HaloTag protein through an Autophagic mechanism .
loading...
    loading...
Cat. No.: HY-148745
CAS No.: 2241517-83-7
Target:  

Drug Derivative HSP

Research Areas:  

Cancer

JG-258 is an inactive negative control for Hsp70 inhibitors. JG-258 is an inactive structural analog of JG-98 (HY-117282), an allosteric inhibitor of heat shock protein 70 (Hsp70) with demonstrated anticancer activity. JG-258 can be used in cancer-related research .
loading...
    loading...
Cat. No.: HY-129658
CAS No.: 1246826-07-2
Target:  

GCGR

Research Areas:  

Metabolic Disease

TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. TT-OAD2 free base has the potential for diabetes treatment .
loading...
    loading...